Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

A bbVie has reported encouraging topline outcomes from the first of two replicate trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib), at both 15mg and 30mg doses in adult and ...

In July 2025, AbbVie announced top line results from one of two parallel studies of the Phase III UP-AA trial evaluating upadacitinib in alopecia areata (AA).

Upadacitinib was found to potentially induce alopecia areata in a patient who used it for almost a year to treat atopic dermatitis, according to a study published in Cureus. 1 Upadacitinib is ...

In the SLEek Phase 2 study, 341 patients undergoing standard lupus therapy were randomized to receive once daily ABBV-599 high dose, ABBV-599 low dose (elsubrutinib 60 mg plus upadacitinib 15 mg ...

In the AS study, a higher proportion of patients receiving upadacitinib 15 mg achieved meaningful improvement vs. placebo, including 30% and 50% reductions in pain; a 70% reduction in pain was ...

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1)at Week 161 ...

Rheumatology > Arthritis Success for Upadacitinib in PsA, Despite Concerns — JAK inhibitor nabs new indication after FDA called for boxed warnings on the class by Nancy Walsh, Contributing ...

Upadacitinib significantly reduced signs and symptoms of both ankylosing spondylitis and nonradiographic axial spondyloarthritis, as well as improved physical function and disease activity ...

Upadacitinib improves joint and skin symptoms in patients with psoriatic arthritis for whom at least one other disease-modifying anti-rheumatic drug (DMARD) didn't work or wasn't well tolerated, a ...

Both upadacitinib and abatacept have demonstrated efficacy in rheumatoid arthritis. To compare them head-to-head, the investigators conducted a double-blind trial at 120 sites in 28 countries ...